Bank of New York Mellon’s Carisma Therapeutics CARM Stock Holding History

Bank of New York Mellon’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-77,712	Closed	-$176K	–	4146
2024 Q1	$176K	Sell	77,712 -5,817	-7%	-$14K	﹤0.01%	3964
2023 Q4	$245K	Sell	83,529 -218	-0.3%	-$648	﹤0.01%	3880
2023 Q3	$354K	Sell	83,747 -326	-0.4%	-$2.06K	﹤0.01%	3732
2023 Q2	$737K	Buy	+84,073	New	+$458K	﹤0.01%	3384
2023 Q1	–	Sell	-6,110	Closed	-$74.5K	–	4389
2022 Q4	$74.5K	Hold	6,110	–	–	﹤0.01%	4172
2022 Q3	$52K	Hold	6,110	–	–	﹤0.01%	4318
2022 Q2	$99K	Sell	6,110 -26,003	-81%	-$298K	﹤0.01%	4224
2022 Q1	$387K	Buy	32,113 +2,457	+8%	+$34.3K	﹤0.01%	3860
2021 Q4	$483K	Buy	29,656 +2,114	+8%	+$42.6K	﹤0.01%	3831
2021 Q3	$437K	Buy	27,542 +4,112	+18%	+$197K	﹤0.01%	3883
2021 Q2	$2.16M	Buy	23,430 +18,864	+413%	+$1.2M	﹤0.01%	2934
2021 Q1	$237K	Sell	4,566 -2,090	-31%	-$98.6K	﹤0.01%	3997
2020 Q4	$179K	Buy	6,656 +3,245	+95%	+$82.3K	﹤0.01%	4002
2020 Q3	$95K	Hold	3,411	–	–	﹤0.01%	3962
2020 Q2	$49K	Sell	3,411 -2,028	-37%	-$27.4K	﹤0.01%	3986
2020 Q1	$61K	Sell	5,439 -28	-0.5%	-$459	﹤0.01%	3943
2019 Q4	$114K	Hold	5,467	–	–	﹤0.01%	4008
2019 Q3	$128K	Hold	5,467	–	–	﹤0.01%	3988
2019 Q2	$164K	Buy	5,467 +2,056	+60%	+$61.6K	﹤0.01%	3963
2019 Q1	$71K	Sell	3,411 -50	-1%	-$863	﹤0.01%	4056
2018 Q4	$98K	Hold	3,461	–	–	﹤0.01%	3961
2018 Q3	$149K	Sell	3,461 -310	-8%	-$12.1K	﹤0.01%	3981
2018 Q2	$147K	Buy	3,771 +1,694	+82%	+$74.6K	﹤0.01%	3958
2018 Q1	$43K	Sell	2,077 -165	-7%	-$3.17K	﹤0.01%	4182
2017 Q4	$37K	Buy	2,242 +224	+11%	+$4.17K	﹤0.01%	4239
2017 Q3	$64K	Hold	2,018	–	–	﹤0.01%	4067
2017 Q2	$63K	Sell	2,018 -206	-9%	-$6.87K	﹤0.01%	4102
2017 Q1	$98K	Buy	2,224 +206	+10%	+$8.58K	﹤0.01%	4036
2016 Q4	$77K	Sell	2,018 -9	-0.4%	-$396	﹤0.01%	4067
2016 Q3	$113K	Sell	2,027 -1,347	-40%	-$100K	﹤0.01%	4013
2016 Q2	$112K	Buy	3,374 +392	+13%	+$9.92K	﹤0.01%	4037
2016 Q1	$19K	Sell	2,982 -1,022	-26%	-$14.1K	﹤0.01%	4171
2015 Q4	$241K	Buy	4,004 +1,022	+34%	+$58K	﹤0.01%	3808
2015 Q3	$144K	Buy	2,982 +1,010	+51%	+$62.3K	﹤0.01%	4009
2015 Q2	$111K	Sell	1,972 -652	-25%	-$92K	﹤0.01%	4024
2015 Q1	$468K	Buy	2,624 +161	+7%	+$35.2K	﹤0.01%	3633
2014 Q4	$585K	Sell	2,463 -17	-0.7%	-$3.81K	﹤0.01%	3556
2014 Q3	$552K	Hold	2,480	–	–	﹤0.01%	3587
2014 Q2	$654K	Buy	2,480 +1,966	+382%	+$486K	﹤0.01%	3522
2014 Q1	$167K	Buy	+514	New	+$154K	﹤0.01%	3894

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $104M AUM

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon's CARM Position: Q2 2024 in Review

Bank of New York Mellon sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 77,712 shares — an estimated $176K sold.

Bank of New York Mellon first reported a position in CARM in Q1 2014 and held it in 40 quarters. The position peaked at $2.16M in Q2 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

Bank of New York Mellon reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
Bank of New York Mellon sold 77,712 Carisma Therapeutics shares in Q2 2024, an estimated $176K.
Bank of New York Mellon first reported a position in Carisma Therapeutics in Q1 2014 and held it in 40 quarters.
Bank of New York Mellon's Carisma Therapeutics position peaked at $2.16M in Q2 2021.
53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.